No Data
No Data
Chengda Pharmaceutical (301201.SZ): Plans to postpone the "Pharmaceutical intermediate project" and "Active pharmaceutical ingredient project" until December 31, 2024.
On June 28th, Gelunhui reported that Chengda Pharmaceutical (301201.SZ) announced that the 5th Board of Directors and the 5th Supervisory Board meetings were held on June 28th, 2024, and approved the proposal to extend the implementation period of some raised funds investment projects. It was agreed to adjust the implementation period of the raised funds investment projects for "pharmaceutical intermediate projects" and "active pharmaceutical ingredient projects" to December 31, 2024.
Chengda Pharmaceutical (301201.SZ): No orders in progress from the Pfizer API factory
Gelonghui, May 14 | Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that currently, the company has no orders from the Pfizer API factory. Please refer to the company's announcement for the information to be disclosed.
ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Chengda Pharmaceutical (301201.SZ): one of the main suppliers of L-carnitine in the world
Gelonghui May 8 丨 Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that the company is one of the main suppliers of L-carnitine in the world. L-carnitine series products include medicinal grade and food/feed additives. The products that were reduced in the early stages were mainly the food/feed additive L-carnitine. Currently, the sales price market for related products has improved slightly, and there is still some uncertainty about the price trend of related products in the future.
Chengda Pharmaceutical (301201.SZ): Some products use synthetic biotechnology such as enzyme catalysis to improve the quality of related products and reduce production costs
Gelonghui, May 8, 丨 Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that some of the company's products use synthetic biotechnology such as enzyme catalysis to improve the quality of related products and reduce production costs. The company will then actively promote the application of enzyme catalysis technology and the upgrading of traditional catalytic technology to drive product process upgrading and quality improvement with new technology, providing more possibilities for future drug development. At the same time, the company invested in the establishment of Shanghai Chengjiutai Biomedical Co., Ltd. at the end of 2023, which will help the company lay out the biomedical sector and expand R&D, production and treatment business in the biological cell industry. In fact
Chengda Pharmaceutical (301201.SZ): 2.03% of shares have been repurchased
Gelonghui, May 7, 丨 Chengda Pharmaceutical (301201.SZ) announced that as of April 30, 2024, the company had repurchased a total of 3,137,500 shares of the company's shares through a dedicated securities account, accounting for 2.03% of the company's current total share capital. The highest transaction price was 22.21 yuan/share, the minimum transaction price was 14.63 yuan/share, and the total transaction amount was 55,266.67 million yuan (excluding transaction fees).
No Data